Abstract
In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Infectious Disorders - Drug Targets
Title: Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Volume: 8 Issue: 4
Author(s): Rolando Vernal and Jose A. Garcia-Sanz
Affiliation:
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Abstract: In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Export Options
About this article
Cite this article as:
Vernal Rolando and Garcia-Sanz A. Jose, Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734197
DOI https://dx.doi.org/10.2174/187152608786734197 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Sentinel Node in Endometrial Cancer: Rationale and Early Experience
Current Women`s Health Reviews Biomedical Applications of Zinc Oxide Nanomaterials
Current Molecular Medicine Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Current State of Development of Genome Analysis in Livestock
Current Genomics Mitochondria-Targeting Therapeutic Strategies for Overcoming Chemoresistance and Progression of Cancer
Current Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Applied Proteomics in Companion Animal Medicine
Current Proteomics Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets